Mutations of the VHL tumour suppressor gene in renal carcinoma (scientific article published on May 1994)

cites work (P2860)

Q42065532	11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice
Q39014919	15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells
Q51126749	2007 Annual Meeting of the Society of Urologic Oncology and the Society of Basic Urologic Research: Introduction.
Q33728365	4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.
Q88792972	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma
Q55208909	A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis.
Q73157865	A 3p21.3 region is preferentially eliminated from human chromosome 3/mouse microcell hybrids during tumor growth in SCID mice
Q92372140	A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma
Q77431624	A PCR generated BsaJ I RFLP in the promoter of the von Hippel-Lindau disease (VHL) tumour suppressor gene
Q91668404	A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2
Q38655110	A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Stu
Q74350783	A case of von Hippel-Lindau disease with bilateral pheochromocytoma, renal cell carcinoma, pelvic tumor, spinal hemangioblastoma and primary hyperparathyroidism
Q45674698	A clear picture of renal cell carcinoma
Q38267103	A clearer view of the molecular complexity of clear cell renal cell carcinoma.
Q74610997	A clinical and molecular genetic analysis of solitary ocular angioma
Q77132622	A common region of allelic loss on chromosome region 3p25.3-26.3 in nasopharyngeal carcinoma
Q34633037	A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma
Q35747277	A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
Q74165044	A familial case of renal cell carcinoma and a t(2;3) chromosome translocation
Q72127267	A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer
Q41340681	A group of NotI jumping and linking clones cover 2.5 Mb in the 3p21-p22 region suspected to contain a tumor suppressor gene.
Q36137398	A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance
Q33261672	A multinodular goiter as the initial presentation of a renal cell carcinoma harbouring a novel VHL mutation.
Q36089988	A novel VHLα isoform inhibits Warburg effect via modulation of PKM splicing
Q28215542	A novel ankyrin repeat-containing gene (Kank) located at 9p24 is a growth suppressor of renal cell carcinoma
Q80826634	A novel germline mutation in the von Hippel-Lindau gene in patients in Kuwait
Q37370106	A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications
Q35774799	A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
Q36316107	A patient with bilateral pheochromocytoma as part of a Von Hippel-Lindau (VHL) syndrome type 2C.
Q33745923	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma
Q36509683	A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma
Q38084210	A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer
Q36509678	A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
Q40716754	A recombinant adenovirus expressing p7(Kip1) induces cell cycle arrest and apoptosis in human 786-0 renal carcinoma cells
Q36222472	A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.
Q48251957	A study on pharmacokinetics of bosentan with systems modeling, Part 2: prospectively predicting systemic and liver exposure in healthy subjects.
Q89774389	A transgenic mouse expressing miR-210 in proximal tubule cells shows mitochondrial alteration: possible association of miR-210 with a shift in energy metabolism
Q40420346	A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas
Q32046901	A whole-genome analysis of allelic changes in renal cell carcinoma by in-gel competitive reassociation
Q73591508	Aberrant expression of Pax-2 mRNA in renal cell carcinoma tissue and parenchyma of the affected kidney
Q55298720	Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas.
Q37401553	Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
Q82876754	Abstracts from the Chemotherapy Foundation Symposium XXIV: Innovative Cancer Therapy for Tomorrow, November 8-11, 2006, New York, New York, USA
Q79426596	Activation of the mTOR signaling pathway in renal clear cell carcinoma
Q46837791	Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
Q36975174	Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors
Q92011463	Adipose-derived exosomes deliver miR-23a/b to regulate tumor growth in hepatocellular cancer by targeting the VHL/HIF axis
Q96811980	Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma
Q36932216	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Q36616711	Adjuvant therapy of renal cell carcinoma
Q33693793	Adrenomedullin as a therapeutic target in angiogenesis
Q33717000	Advances in the molecular basis of renal neoplasia
Q34194088	Aerobic glycolysis: a novel target in kidney cancer
Q80100893	Age-specific familial risks for renal cell carcinoma with evidence on recessive heritable effects
Q37110972	All along the watchtower: is the cilium a tumor suppressor organelle?
Q74332373	Allelic Deletion of VHL Gene Detected in Papillary Tumors of the Broad Ligament, Epididymis, and Retroperitoneum in von Hippel-Lindau Disease Patients
Q53461614	Allelic Loss at the Tuberous Sclerosis (Tsc2) Gene Locus in Spontaneous Uterine Leiomyosarcomas and Pituitary Adenomas in the Eker Rat Model
Q35763943	Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.
Q35782701	Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients
Q36636648	Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma
Q56418625	Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia
Q37724576	Alterations in VHL as potential biomarkers in renal-cell carcinoma
Q51797120	Altered expression of key cell cycle regulators in renal cell carcinoma associated with Xp11.2 translocation.
Q42469993	Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity
Q34385809	An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation
Q34387297	An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects
Q81522026	An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications
Q40914690	An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association
Q41882621	An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.
Q38020665	An overview of renal cell cancer: pathology and genetics
Q90329969	An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC)
Q77652358	Analysis of 3p allelic losses in renal cell carcinomas: comparison with cytogenetic results
Q41919666	Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Q40922473	Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion
Q33473894	Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma
Q41895705	Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma
Q73590491	Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development
Q48694729	Analysis of renal cell transformation following exposure to trichloroethene in vivo and its metabolite S-(dichlorovinyl)-L-cysteine in vitro
Q36643591	Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas.
Q60536655	Analysis of von Hippel—Lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity
Q91198240	Ancillary studies in fine needle aspiration of the kidney
Q42377198	Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma
Q37119218	Angiogenesis and angiogenic inhibitors in renal cell carcinoma
Q38405503	Angiogenesis and expression of vascular endothelial growth factor, tumour necrosis factor-α and hypoxia inducible factor-1α in canine renal cell carcinoma.
Q96769712	Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT-enhancer binding protein beta and hypoxia-inducible factor-2α and subsequent secretion of interleukin-6, interleukin-8, and vascular endothelial growth factor in the Caki-1 cle
Q37354411	Anti-angiogenesis approach to genitourinary cancer treatment.
Q36794815	Anti-angiogenic therapy in renal cell cancer
Q38086799	Anti-vascular endothelial growth factor therapy in the era of personalized medicine
Q46427304	Antiangiogenics: new therapeutic standards in metastatic kidney cancer
Q42643751	Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma
Q81008246	Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo
Q36414377	Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment
Q36105159	Application of molecular diagnostic techniques to renal epithelial neoplasms
Q27026961	Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma
Q52568969	Are Pax proteins potential therapeutic targets in kidney disease and cancer?
Q33267915	Array-CGH and multipoint FISH to decode complex chromosomal rearrangements
Q43707243	Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma.
Q83945290	Association of RASSF1A genotype and haplotype with the progression of clear cell renal cell carcinoma in Japanese patients
Q95720985	Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma
Q74381357	Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors
Q80403823	Associations between VHL genotype and clinical phenotype in familial von Hippel-Lindau disease
Q79741794	Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas
Q34280223	BAP1 loss defines a new class of renal cell carcinoma
Q91447532	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
Q34580977	Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis
Q37899447	Basic research in kidney cancer
Q51135496	Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.
Q37117085	Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
Q77493885	Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma
Q77132898	Biallelic mutations of the Tsc2 gene in chemically induced rat renal cell carcinoma
Q58862075	Bilateral multiple renal oncocytomas and cysts associated with a constitutional translocation (8;9)(q24.1;q34.3) and a rare constitutional VHL missense substitution
Q77354389	Bilateral non-familial renal cell carcinoma
Q27933200	Binding of elongin A or a von Hippel-Lindau peptide stabilizes the structure of yeast elongin C
Q24336712	Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Q39115134	Biologic implications of genetic changes in head and neck squamous cell carcinogenesis
Q36240186	Biological Features of a Renal Cell Carcinoma Cell Line Derived from Spinal Metastasis
Q34606543	Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma
Q35943769	Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
Q37544209	Biomarkers in renal cell carcinoma
Q40759700	Biomarkers of renal cell carcinoma. Past and future considerations
Q38091258	Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone
Q24676422	Ca2+-activated K+ channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1alpha and the von Hippel-Lindau protein
Q37672483	Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Q37154528	Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma
Q40138683	Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray
Q37145167	Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies
Q37177275	Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant
Q36475753	Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma
Q38154550	Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment
Q34781692	Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells
Q34592514	Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Q38214442	Cell cycle progression in response to oxygen levels.
Q47711163	Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.
Q57341426	Cellular Respiration and Tumor Suppressor Genes
Q84517686	Characterization of N-diethylnitrosamine-initiated and ferric nitrilotriacetate-promoted renal cell carcinoma experimental model and effect of a tamarind seed extract against acute nephrotoxicity and carcinogenesis
Q92677711	Characterization of renal cell carcinoma-associated constitutional chromosome abnormalities by genome sequencing
Q24317659	Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations
Q28252043	Characterization of the gene (VBP1) and transcript for the von Hippel-Lindau binding protein and isolation of the highly conserved murine homologue
Q72820907	Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications
Q91697989	Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin
Q38031654	Chemistry of DNA minor groove binding agents
Q30435873	Chemokines as therapeutic targets in renal cell carcinoma
Q60445173	Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis
Q36052220	Chemotherapy in metastatic renal cell cancer
Q77614838	Childhood cerebellar hemangioblastoma does not predict germline or somatic mutations in the von Hippel-Lindau tumor suppressor gene
Q35754544	Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes
Q28360494	Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features.
Q38907345	Chronic lymphocytic lymphoma and concomitant renal cell carcinoma (Clear Cell Type): Review of the literature
Q91546038	Circular RNA hsa_circ_001895 serves as a sponge of microRNA-296-5p to promote clear cell renal cell carcinoma progression by regulating SOX12
Q27023770	Circulating biomarkers in advanced renal cell carcinoma: clinical applications
Q47726109	Clear cell carcinomas of the ovary and kidney: clarity through genomics
Q90628353	Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?
Q45294676	Clear cell type of renal cell carcinoma with numerous hyaline globules: a diagnostic pitfall
Q77495421	Clear-cell and papillary carcinoma of the kidney: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification, cytogenetics, and fluorescence in situ hybridization
Q45372047	Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases
Q79960183	Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports
Q48615473	Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel-Lindau disease. Report of four cases.
Q43010122	Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation
Q37901850	Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Q43806776	Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Q40443803	Clinical aspects of renal tumors
Q51912272	Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Q40942344	Clinical features and molecular genetics of Von Hippel-Lindau disease
Q37469438	Clinical implications of hypoxia inducible factor in renal cell carcinoma.
Q46014175	Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Q74583095	Clinical significance of allelic loss of chromosome region 5q22.3 approximately q23.2 in nonpapillary renal cell carcinoma
Q58701873	Clinicopathologic Significance of Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
Q81725970	Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma
Q33937658	Cloning a calcium channel alpha2delta-3 subunit gene from a putative tumor suppressor gene region at chromosome 3p21.1 in conventional renal cell carcinoma
Q73004475	Closing in on another renal cancer suppressor locus near chromosome 3p14
Q35087893	Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein
Q50199823	Clusterin promotes growth and invasion of clear cell renal carcinoma cell by upregulation of S100A4 expression
Q90628173	Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer
Q35796053	Coexpression of transforming growth factor-alpha and épidermal growth factor receptor in capillary hemangioblastomas of the central nervous system
Q39398836	Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines
Q101474649	Combination therapy in metastatic renal cell carcinoma: Back to the future?
Q91006190	Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Q52826627	Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma.
Q34193780	Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma
Q37613493	Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?
Q39382008	Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression.
Q38303772	Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma
Q64971389	Comparative Expression Profiling of Wild Type Drosophila Malpighian Tubules and von Hippel-Lindau Haploinsufficient Mutant.
Q34509260	Comparative sequence analysis of the VHL tumor suppressor gene
Q54298122	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.
Q89621491	Comprehensive Analysis of Copy Number Variations in Kidney Cancer by Single-Cell Exome Sequencing
Q91126588	Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology
Q34509847	Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes
Q77841215	Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters
Q49651208	Compromised JMJD6 histone demethylase activity impacts on VHL gene repression in preeclampsia
Q27336383	Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome
Q46330651	Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene
Q53668297	Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas.
Q33682281	Congenital anomalies and genetic disorders in families of children with central nervous system tumours
Q103831934	Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma
Q34598015	Contemporary epidemiology of renal cell cancer
Q26777412	Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis
Q38119888	Cooperation and antagonism among cancer genes: the renal cancer paradigm
Q83761819	Copy number profiling in von Hippel-Lindau disease renal cell carcinoma
Q73254713	Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence
Q55004198	Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Q37233603	CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.
Q35433886	Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only
Q60922626	Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment
Q36452714	Current status and perspective of antiangiogenic therapy for cancer: urinary cancer
Q46670429	Current strategies in the treatment of renal-cell cancer: targeted therapies
Q36710400	Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists
Q37737016	Cystic renal tumors: new entities and novel concepts
Q80324391	Cytogenetic alterations in renal tumors: a study of 38 Southeast Asian patients
Q55670950	Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3)(q35;q21)
Q70822994	Cytogenetic characterization of a familial papillary renal cell carcinoma
Q77508304	Cytologic analysis of papillary renal cell carcinoma
Q44192570	DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras.
Q74449047	Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma
Q91341105	Defining Signatures of Arm-Wise Copy Number Change and Their Associated Drivers in Kidney Cancers
Q39178416	Degrons in cancer
Q89719539	Deletion of Von Hippel-Lindau Interferes with Hyper Osmolality Induced Gene Expression and Induces an Unfavorable Gene Expression Pattern
Q38022052	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
Q39019458	Deregulated expression of VHL mRNA variants in papillary thyroid cancer.
Q84210212	Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma
Q27333673	Design and analysis of a Petri net model of the Von Hippel-Lindau (VHL) tumor suppressor interaction network
Q73799794	Detailed microsatellite analysis of chromosome 3p region in non-papillary renal cell carcinomas
Q38715906	Detecting circulating tumor DNA in renal cancer: An open challenge.
Q57631389	Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation
Q73187074	Detection of a novel germline mutation in the von Hippel-Lindau tumour-suppressor gene by fluorescence-labelled base excision sequence scanning (F-BESS)
Q73555871	Detection of gene deletion in single metastatic tumour cells in lymphnode tissue by fluorescent in-situ hybridisation
Q38461457	Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: utilization of microdissection and polymerase chain reaction in archival tissues
Q33573577	Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma
Q36643235	Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma
Q82142251	Determination of vhl gene mutations in sporadic renal cell carcinoma
Q53430411	Development of high-grade renal cell carcinomas in rats independently of somatic mutations in the Tsc2 and VHL tumor suppressor genes.
Q40407399	Diagnosis and prognosis of renal-cell tumors: a molecular approach
Q40535795	Diagnosis and the new genetics
Q73223860	Diagnosis of renal cancer by molecular urinalysis
Q33481999	Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes
Q40535916	Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney
Q52880866	Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.
Q58323654	Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes
Q52061865	Distance-based reconstruction of tree models for oncogenesis.
Q34323668	Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity
Q34132481	Dna adducts, mutations, and cancer 2000.
Q37799821	Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Q36916355	Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma
Q24644903	Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes
Q40645070	Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells
Q35899912	Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma.
Q39490219	Downregulation of fumarate hydratase is related to tumorigenesis in sporadic renal cell cancer.
Q38737865	Drug Development Against Metastatic Cancers
Q28086796	Dysregulation of ubiquitin ligases in cancer
Q34707583	Early identification of patients with von Hippel-Lindau disease at risk for pheochromocytoma
Q59571893	Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma
Q52618590	Effects of point mutations in pVHL on the binding of HIF-1α.
Q43276017	Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Q35022463	Elevated estrogen receptor-α in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction
Q47855049	Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer
Q24336681	Elongin (SIII): A Multisubunit Regulator of Elongation by RNA Polymerase II
Q36421535	Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling
Q36302842	Emerging drugs for renal cell carcinoma
Q84159104	Emerging drugs for renal cell carcinoma
Q38815893	Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma
Q26862957	Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside
Q38176255	Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response
Q81117362	Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): report of two cases with analysis of the VHL gene
Q50435582	Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): sine qua non radiology-pathology and the University of Texas MD Anderson Cancer Center experience
Q47911795	Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression
Q73623166	Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region
Q57608167	Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis
Q36518228	Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
Q34182910	Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Q40352903	Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma
Q88985337	Epigenetics in renal cell cancer: mechanisms and clinical applications
Q41574276	Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Q40908590	Establishment and characterization of seven human renal cell carcinoma cell lines
Q78139556	Establishment of experimental conditions for the rapid detection of mutations in the von Hippel-Lindau gene by parallel temperature gradient gel electrophoresis
Q97428885	Etiologic heterogeneity of clear-cell and papillary renal cell carcinoma in the Netherlands Cohort Study
Q92382571	Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis
Q53583449	Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Q35787295	Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization
Q41108912	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor
Q34417931	Everolimus - a new approach in the treatment of renal cell carcinoma
Q38997782	Evidence for aldosterone-dependent growth of renal cell carcinoma
Q80552108	Evidence of graft-versus-tumour effect following allogeneic haematopoietic stem cell transplantation in renal cancer other than clear cell type
Q57608170	Evolution of VHL tumourigenesis in nerve root tissue
Q38676794	Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma
Q35674241	Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma.
Q60445178	Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy
Q53668779	Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas.
Q73467027	Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene
Q50178478	Expression of VHL and HIF-1α and Their Clinicopathologic Significance in Benign and Malignant Lesions of the Gallbladder
Q80357056	Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation
Q38491062	Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation
Q45134199	Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma
Q41328849	Expression of nm23 in cell lines derived from patients with metastatic renal cell carcinoma
Q36437594	Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis
Q24300575	Expression of the ammonia transporter, rh C glycoprotein, in normal and neoplastic human kidney
Q43110710	Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer.
Q35842166	Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers
Q57660049	Extraneural Hemangioblastoma
Q26800869	Extraneural hemangioblastoma of the kidney: the challenge for clinicopathological diagnosis
Q49496028	Extraneuraxial Hemangioblastoma: Clinicopathologic Features and Review of the Literature
Q45980708	FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma.
Q34515955	Familial adult renal neoplasia
Q35434654	Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes
Q35687676	Familial renal cancer: molecular genetics and surgical management
Q40410169	Familial renal cell carcinoma: review of recent molecular genetics
Q78582609	Familial risk of cancer by site and histopathology
Q39798868	Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
Q38175454	Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
Q73467010	Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study
Q38414604	Fluorescent In-situ Hybridization Study of Non-papillary Oncocytic/Eosinophilic Renal Cell Carcinoma
Q35893624	Focus on kidney cancer
Q33886538	Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.
Q46006357	Fragile histidine triad (FHIT) gene and its association with p53 protein expression in the progression of gall bladder cancer.
Q58006216	Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification
Q37275151	Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.
Q35706831	Functional Subunits of Eukaryotic Chaperonin CCT/TRiC in Protein Folding
Q36648074	Functional evaluation of the apoptosome in renal cell carcinoma
Q73784996	Functioning thoracic paraganglioma: association with Von Hippel-Lindau syndrome
Q81342868	Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma
Q53847052	Gene expression of GLUT isoforms and VHL in oral squamous cell carcinoma.
Q53612481	Gene expression profiling of renal cell carcinoma: a DNA macroarray analysis.
Q24814730	Gene expression profiling predicts survival in conventional renal cell carcinoma
Q35920812	Generation and Characterisation of a Pax8-CreERT2 Transgenic Line and a Slc22a6-CreERT2 Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells
Q52590924	Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma.
Q36028393	Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells
Q98200998	Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets
Q40972502	Genetic alterations in breast cancer.
Q74812391	Genetic analysis of 2 cases of clear cell renal cancer in 2 sisters
Q71048260	Genetic analysis of synchronous mucinous tumors of the ovary and appendix
Q51965383	Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Q52856655	Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
Q40718800	Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter
Q81267790	Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy
Q36794767	Genetic basis of kidney cancer: a model for developing molecular-targeted therapies
Q36354841	Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics
Q71343783	Genetic changes in the origin and development of renal cell carcinoma (RCC)
Q35064232	Genetic disorders and renal cell carcinoma.
Q80183290	Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis
Q74128948	Genetic identification of bilateral primary or metastatic nonpapillary renal cell carcinoma
Q57608157	Genetic insights into the hypoxia-inducible factor (HIF) pathway
Q39023793	Genetic predisposition to kidney cancer
Q34291328	Genetic testing by cancer site: urinary tract
Q37054515	Genetics and epigenetics of renal cell cancer
Q35838967	Genome-wide mapping of Hif-1α binding sites in zebrafish
Q37401031	Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays
Q33947929	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma
Q35646364	Genomic alterations in renal tumours: what have we learned in the era of comparative genomic hybridisation?
Q36646352	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Q96610153	Genomic profiling in renal cell carcinoma
Q46635938	Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma
Q90899773	Genomics and clinical correlates of renal cell carcinoma
Q38023071	Genomics and epigenomics of renal cell carcinoma.
Q33677726	Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A
Q44230145	Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.
Q74817219	Genotype-phenotype correlations in von Hippel-Lindau disease
Q55312690	Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: an extended study of 77 families.
Q35889809	Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
Q45345804	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Q79354832	Germline mutation of von Hippel-Lindau (VHL) gene 695 G>A (R161Q) in a patient with a peculiar phenotype with type 2C VHL syndrome
Q58862079	Germline mutations detected in the von Hippel-Lindau disease tumor suppressor gene by Southern blot and direct genomic DNA sequencing
Q44847029	Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype
Q44847047	Germline mutations in the von Hippel-Lindau gene in Italian patients.
Q92564013	Germline polymorphisms in the Von Hippel-Lindau and Hypoxia-inducible factor 1-alpha genes, gene-environment and gene-gene interactions and renal cell cancer
Q55172634	Global isoform-specific transcript alterations and deregulated networks in clear cell renal cell carcinoma.
Q46961036	Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha
Q51158842	Gramicidin A: A New Mission for an Old Antibiotic.
Q89830041	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention
Q44068443	HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron
Q36609852	HIF and fumarate hydratase in renal cancer
Q35086143	HIF hydroxylation and the mammalian oxygen-sensing pathway
Q29615945	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability
Q38666170	HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Q35564188	HIF-1: an oxygen response system with special relevance to the kidney
Q35891283	HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation
Q38274783	HIF1α expression under normoxia in prostate cancer--which pathways to target?
Q92159808	HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathway
Q36839571	Harnessing synthetic lethal interactions in anticancer drug discovery
Q35099516	Heat shock protein 90 as a molecular target for cancer therapeutics
Q36187025	Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Q86443035	Hemangioblastoma of the gastrointestinal tract: a first case
Q42858934	Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes
Q35609575	Hereditary kidney cancer
Q37287088	Hereditary kidney cancer: unique opportunity for disease-based therapy.
Q34318458	Hereditary papillary renal cell carcinoma: clinical studies in 10 families
Q41046229	High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation.
Q74688598	High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas
Q59526211	High incidence of renal tumours in vitamins A and E synthesis workers: A new cause of occupational cancer?
Q30827424	High telomerase activity correlates with the stabilities of genome and DNA ploidy in renal cell carcinoma
Q81409194	High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma
Q35786795	High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma
Q35868041	Highly penetrant hereditary cancer syndromes.
Q38473548	Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients
Q39700386	Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Q33735233	Histopathology and molecular genetics of renal tumors toward unification of a classification system
Q57209343	Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes
Q33765677	Hypermethylation of tumor suppressor genes in cancer
Q51962814	Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study.
Q26863298	HypoxamiRs and cancer: from biology to targeted therapy
Q92918176	Hypoxia and aging
Q40213183	Hypoxia and renal cell carcinoma: The influence of HIF1A+1772C/T functional genetic polymorphism on prognosis
Q91129506	Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)-mediated induction of the long noncoding RNA NICI
Q33543092	Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification
Q47887318	Hypoxia inducible factor (HIF): its central role in renal cell cancer targeted therapy
Q40356897	Hypoxia requires notch signaling to maintain the undifferentiated cell state
Q37234734	Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
Q38938089	Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.
Q90837994	Hypoxia-inducible factor 2α: a novel target in gliomas
Q36857564	Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells
Q26749159	Hypoxic control of metastasis
Q52645855	Hypoxic marker CA IX and adhesion mediator β-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Q42070258	Hypoxic regulation of the noncoding genome and NEAT1.
Q40232799	IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells
Q55043368	Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.
Q40415541	Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array
Q92068655	Identification of Four Pathological Stage-Relevant Genes in Association with Progression and Prognosis in Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis
Q24634004	Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma
Q28203647	Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor
Q57384547	Identification of a newVHLexon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease
Q98623305	Identification of anti-tumoral feedback loop between VHLα and hnRNPA2B1 in renal cancer
Q38848220	Identification of genes associated with renal cell carcinoma using gene expression profiling analysis
Q24299968	Identification of novel VHL target genes and relationship to hypoxic response pathways
Q38304283	Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling
Q36718988	Identification of somatic chromosomal abnormalities in hypothalamic hamartoma tissue at the GLI3 locus.
Q39832009	Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein
Q36718934	Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics
Q24654714	Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex
Q57695829	Identifizierung VHL-assoziierter Veränderungen im klarzelligen Nierenzellkarzinom
Q40286789	Immune and genetic therapies for advanced renal cell carcinoma.
Q34612711	Immunoaffinity Enrichment and Liquid Chromatography-Selected Reaction Monitoring Mass Spectrometry for Quantitation of Carbonic Anhydrase 12 in Cultured Renal Carcinoma Cells
Q73227598	Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
Q35189579	Impact of genetics on the diagnosis and treatment of renal cancer
Q37780020	Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Q43282347	Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells
Q51331802	Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis.
Q37069569	Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
Q47934677	In silico investigation of PHD-3 specific HIF1-α proline 567 hydroxylation: a new player in the VHL/HIF-1α interaction pathway?
Q89752121	Inactivation of BRM/SMARCA2 sensitizes clear cell renal cell carcinoma to histone deacetylase complex inhibitors
Q28590550	Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice
Q47981361	Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis
Q40296387	Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.
Q28272109	Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1
Q30573857	Inferring tree models for oncogenesis from comparative genome hybridization data
Q36549605	Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells
Q38342047	Infrequent alteration of the DPC4 tumor suppressor gene in renal cell carcinoma.
Q77113259	Inherited carcinomas of the kidney
Q34019599	Inherited epithelial tumors of the kidney: old and new diseases
Q44043145	Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Q24800550	Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth
Q34549454	Inhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain
Q24336629	Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein
Q54283940	Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma.
Q36074111	Insulin-like growth factor-1 signaling in renal cell carcinoma
Q27852382	Integrated molecular analysis of clear-cell renal cell carcinoma
Q33799049	Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma
Q37696197	Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma
Q53627986	Integrative tumor board: metastatic renal cell carcinoma: naturopathic medicine.
Q41242833	Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.
Q37149909	Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications
Q40946483	Intrinsic drug resistance in primary and metastatic renal cell carcinoma
Q35067209	Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma
Q36696226	Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma.
Q44089850	Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Q57272195	Involvement of multiple loci on chromosome 3 in renal cell cancer development
Q35891379	Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein
Q34478868	KLF4, p21 and context-dependent opposing forces in cancer
Q40002571	Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression
Q36675387	Kidney cancer therapy: new perspectives and avenues
Q40831882	Kidney cancer.
Q36366495	Kidney cancer: identification of novel targets for therapy
Q37728343	Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.
Q34589207	Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
Q92087490	LC3C-Mediated Autophagy Selectively Regulates the Met RTK and HGF-Stimulated Migration and Invasion
Q37165231	LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer
Q92123922	LRRC19-A Bridge between Selenium Adjuvant Therapy and Renal Clear Cell Carcinoma: A Study Based on Datamining
Q44763099	Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma
Q38238966	Landmarks in the diagnosis and treatment of renal cell carcinoma
Q84696228	Linking toxicity to the target
Q33821055	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma
Q57914544	Loss of HNF1? function in human renal cell carcinoma: Frequent mutations in theVHL gene but not theHNF1? gene
Q47117026	Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis
Q24299088	Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours
Q37126195	Loss of VHL promotes progerin expression, leading to impaired p14/ARF function and suppression of p53 activity.
Q44605433	Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma
Q36730935	Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array
Q73923938	Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas
Q71769244	Loss of heterozygosity on chromosome arm 3p in nasopharyngeal carcinoma
Q72046516	Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel‐lindau disease‐associated, and familial pheochromocytoma
Q73227572	Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma
Q74141948	Loss of imprinting of igf2 in renal-cell carcinomas
Q33998089	Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth
Q44159799	Loss of the Birt-Hogg-Dubé gene product folliculin induces longevity in a hypoxia-inducible factor-dependent manner
Q61946742	Losses at 3p common deletion sites in subtypes of kidney tumours: histopathological correlations
Q27851432	Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma
Q53459268	Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate.
Q44456560	MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma
Q91754912	MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma
Q28578563	MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression
Q37718458	MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway.
Q35669189	MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism
Q96684667	Macrophage HIF-1α is an independent prognostic indicator in kidney cancer
Q71574846	Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis
Q38180744	Management of metastatic kidney cancer in the era of personalized medicine
Q74639003	Management of renal cell carcinoma in von Hippel-Lindau disease
Q36395197	Management of von Hippel-Lindau-associated kidney cancer
Q37503817	Manipulation of the HIF-Vegf pathway rescues methyl tert-butyl ether (MTBE)-induced vascular lesions
Q101124442	Mass Spectrometry-Based Metabolic Fingerprinting Contributes to Unveil the Role of RSUME in Renal Cell Carcinoma Cell Metabolism
Q36731136	Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer
Q28272747	Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy
Q49832801	Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro
Q38546245	Metabolic alterations in renal cell carcinoma
Q24600512	Metabolism of kidney cancer: from the lab to clinical practice
Q37453142	Metachronous bilateral renal cell carcinoma with an interval of more than 10 years
Q84983264	Metachronous clear cell carcinoma of the tongue and kidney: a diagnostically challenging coincidence
Q34417804	Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
Q73048375	Metastatic renal cell carcinoma in a child: 11-year disease-free survival following surgery
Q64240759	Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report
Q43583310	Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
Q53351901	Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma.
Q24631957	Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
Q26852641	MicroRNAs in the pathogenesis of cystic kidney disease
Q77959493	Microsatellite analysis reveals deletion of a large region at chromosome 8p in conventional renal cell carcinoma
Q30786619	Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology
Q36484119	Mitochondrial disorders in renal tumors.
Q47793757	Mitotic spindle misorientation in cancer--out of alignment and into the fire
Q46856592	Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
Q101407217	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Q34987420	Molecular alterations in sporadic breast cancer
Q73704814	Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15)
Q84571507	Molecular analysis of germline t(3;6) and t(3;12) associated with conventional renal cell carcinomas indicates their rate-limiting role and supports the three-hit model of carcinogenesis
Q37332599	Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms
Q46408470	Molecular basis of targeted therapy in metastatic renal cancer
Q28220414	Molecular basis of the VHL hereditary cancer syndrome
Q77752042	Molecular biology of lung cancer
Q36678672	Molecular biology of renal cell cancer and the identification of therapeutic targets
Q35789932	Molecular classification of renal tumors by gene expression profiling
Q40971282	Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma
Q52828398	Molecular cytogenetic analysis of 17 renal cancer cell lines: increased copy number at 5q31-33 in cell lines from nonpapillary carcinomas.
Q47880488	Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status
Q34065685	Molecular diagnosis and therapy of kidney cancer
Q35782667	Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites
Q42803057	Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis
Q40429882	Molecular foundations of cancer: New targets for intervention
Q35636300	Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas
Q43010632	Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma
Q77357835	Molecular genetic analysis of the von Hippel-Lindau and human peroxisome proliferator-activated receptor gamma tumor-suppressor genes in adenocarcinomas of the gastroesophageal junction
Q71127418	Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumour suppressor gene in gonadal tumours
Q50092603	Molecular genetic diagnosis of von Hippel-Lindau disease: analysis of five Japanese families
Q35022055	Molecular genetics and histopathologic features of adult distal nephron tumors
Q33729097	Molecular genetics of clear-cell renal cell carcinoma
Q36105155	Molecular genetics of familial renal cell carcinoma syndromes
Q35598229	Molecular genetics of kidney cancer
Q41720979	Molecular genetics of renal carcinogenesis
Q74736163	Molecular genetics of renal cell carcinoma
Q26825512	Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?
Q37099355	Molecular markers for predicting prognosis of renal cell carcinoma
Q38131134	Molecular markers to predict response to therapy
Q35089301	Molecular mechanisms of renal development
Q37000269	Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas
Q36492055	Molecular pathogenetics of renal cancer
Q33982903	Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays.
Q73645664	Molecular targeting of VHL gene pathway in clear cell kidney cancer
Q34707607	Molecular-based therapies for renal cell carcinoma
Q36334896	Molecularly targeted therapy in renal cell carcinoma
Q91810878	Monocarboxylate transporter 1 and monocarboxylate transporter 4 in cancer-endothelial co-culturing microenvironments promote proliferation, migration, and invasion of renal cancer cells
Q42186975	Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model
Q80464963	Morphologic and molecular characterization of renal cell carcinoma in children and young adults
Q38967799	Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification
Q35753186	Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis
Q41439628	Mutagenic and epigenetic effects of DNA methylation
Q34144574	Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility
Q71398601	Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas
Q71398598	Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system
Q73272320	Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour
Q51035684	Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1alpha.
Q77303558	Mutation of von Hippel-Lindau tumor suppressor gene in a sporadic endolymphatic sac tumor
Q50310038	Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients
Q33682913	Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas
Q77985962	Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma
Q29937783	Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC
Q39604051	Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma
Q64249111	N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis
Q41967990	NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies
Q41605739	Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
Q34104223	Needle core biopsies provide ample material for genomic and proteomic studies of kidney cancer: observations on DNA, RNA, protein extractions and VHL mutation detection
Q37286026	Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
Q35310741	Nephrotoxicity of recent anti-cancer agents
Q48196926	Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma
Q40961524	Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function
Q34538603	Neurological Management of Von Hippel-Lindau Disease
Q38664266	New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas
Q44747905	New antiangiogenic agents for renal cell carcinoma: interferon alfa and thalidomide
Q36691810	New drug therapies for advanced renal cell carcinoma
Q42631757	New insights into von Hippel-Lindau function highlighted by investigation of the trichloroethylene-induced p.P81S hotspot mutation
Q37596915	New treatment approaches in renal cell carcinoma
Q90609011	Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine
Q34206517	Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes
Q36913101	Nitric oxide and hypoxia
Q74137968	No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis
Q37822638	Non-clear cell advanced kidney cancer: is there a gold standard?
Q35692212	Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report
Q57212292	Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma
Q34409187	Novel approaches in the therapy of metastatic renal cell carcinoma.
Q37685596	Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.
Q36045973	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents
Q82562299	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents
Q38467569	Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas
Q53330035	Novel somatic mutations of the VHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells.
Q34392028	Novel three missense mutations observed in Von Hippel-Lindau gene in a patient reported with renal cell carcinoma
Q34603364	Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma
Q37701211	Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density
Q24651568	Nucleostemin mRNA is expressed in both normal and malignant renal tissues
Q33636256	Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies
Q84582207	Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease
Q91531330	On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy
Q55618938	Oncogenic miR-425-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma.
Q38008023	Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?
Q53320370	Over expression of hypoxia-inducible protein 2, hypoxia-inducible factor-1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure.
Q36016797	Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma
Q43980382	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial
Q38822454	Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Q38357715	Overexpression of KIT in chromophobe renal cell carcinoma
Q42549996	Overexpression of integrin-associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate
Q51582002	Overexpression of miR-210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells.
Q54765102	Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Q35565483	Oxygen sensing in cancer
Q34611016	Oxygen sensors and angiogenesis
Q28647626	Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein
Q38122565	PBRM1 and BAP1 as novel targets for renal cell carcinoma
Q37596748	PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
Q92943300	PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression
Q37749481	PHD2 in tumour angiogenesis
Q38889724	PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways
Q50784588	PRCC-TFE3 renal cell carcinoma in a boy with a history of contralateral mesoblastic nephroma.
Q91596984	PRDM16 suppresses HIF-targeted gene expression in kidney cancer
Q91560799	Pan-cancer genomic amplifications underlie a WNT hyperactivation phenotype associated with stem cell-like features leading to poor prognosis
Q61226159	Pan-cancer genomic amplifications underlie a Wnt hyperactivation phenotype associated with stem cell-like features leading to poor prognosis
Q34364668	Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population
Q38478525	Papillary renal cell carcinoma: quantitation of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy
Q85072259	Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma
Q36285539	Parathyroid hormone-related protein in human renal cell carcinoma
Q38447341	Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival.
Q54135611	Pathological and Clinical Features and Management of Central Nervous System Hemangioblastomas in von Hippel-Lindau Disease.
Q38030685	Pathology of genitourinary malignancies: implications for clinical management
Q36713480	Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment.
Q38483900	Patterns of aneuploidy in stage IV clear cell renal cell carcinoma revealed by comparative genomic hybridization and spectral karyotyping
Q41127733	Pax-2, kidney development, and oncogenesis
Q34207205	Pazopanib for the treatment of patients with advanced renal cell carcinoma
Q37862259	Pazopanib for the treatment of renal cancer
Q37748042	Pazopanib: Clinical development of a potent anti-angiogenic drug
Q58104072	Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?
Q92272936	Perivascular Neuropilin-1 expression is an independent marker of improved survival in renal cell carcinoma
Q37457275	Perspective: Beyond the genome
Q39095194	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma
Q79318186	Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
Q33813718	Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
Q36047391	Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor
Q34497997	Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models
Q35592187	Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma
Q45101302	Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma.
Q77308149	Polyploidization and losses of chromosomes 1, 2, 6, 10, 13, and 17 in three cases of chromophobe renal cell carcinomas
Q54710672	Positive correlation between allelic loss at chromosome 14q24-31 and poor prognosis of patients with renal cell carcinoma.
Q78052855	Positive expression of HIF-2alpha/EPAS1 in invasive bladder cancer
Q37285776	Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene
Q38970282	Precision medicine from the renal cancer genome
Q90737500	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors
Q83462674	Preimplantation genetic diagnosis using fluorescent in situ hybridization for cancer predisposition syndromes caused by microdeletions
Q89793198	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes
Q41659630	Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications
Q24813050	Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study
Q40841893	Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma
Q47272377	Primary capillary hemangioblastoma of peripheral soft tissues
Q78213661	Processed pseudogene from the von Hippel-Lindau disease gene is located on human chromosome 1
Q26827319	Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
Q26749393	Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
Q92154621	Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
Q36816038	Prognostic biomarkers in renal cell carcinoma
Q44272543	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Q50688764	Prognostic significance of erythropoietin expression in human renal cell carcinoma.
Q40419210	Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma
Q90368775	Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
Q54583873	Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
Q39718603	Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.
Q36585720	Proteostasis modulators prolong missense VHL protein activity and halt tumor progression
Q36910720	Pseudohypoxic pathways in renal cell carcinoma
Q42662359	Quantifying cancer progression with conjunctive Bayesian networks
Q54707675	Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
Q48123819	RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.
Q35924637	RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis
Q26853207	RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis
Q73561184	Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2
Q34779834	Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography
Q38071583	Rational therapy for renal cell carcinoma based on its genetic targets
Q46591527	Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
Q89839542	Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue-based research
Q38108392	Recent advances in the treatment of metastatic renal cell carcinoma
Q47899328	Recent developments in small molecule therapies for renal cell carcinoma
Q34138129	Recessive oncogenes: current status
Q102321421	Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors
Q38171376	Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.
Q35462032	Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system
Q36741647	Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration.
Q39052352	Reduced expression of Slit2 in renal cell carcinoma
Q28478577	Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion
Q71937674	Refining a proximal breakpoint cluster at chromosome 3p11.2 in non-papillary renal cell carcinomas
Q92390135	Regulation of Stem Cells by Cullin-RING Ligase
Q38881445	Regulation of cancer stem cells by RING finger ubiquitin ligases
Q24523680	Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2
Q34530199	Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.
Q24301119	Regulation of receptor for activated C kinase 1 protein by the von Hippel–Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness
Q42288643	Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma
Q40812865	Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma
Q35792041	Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.
Q57049453	Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model
Q38854862	Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved
Q74453899	Renal Cell Carcinoma Metastatic to the Thyroid Gland: A Comparative Molecular Study Between the Primary and the Metastatic Tumor
Q41018679	Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status
Q58104118	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers
Q58376206	Renal Tumors in the Birt-Hogg-Dubé Syndrome
Q47266916	Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery
Q38125117	Renal cancer in von Hippel-Lindau disease and related syndromes
Q35660579	Renal cancer treatment: a review of the literature.
Q37153397	Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy
Q34468262	Renal cancer: molecular mechanisms and newer therapeutic options
Q38185177	Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization.
Q30235364	Renal cell carcinoma
Q73669457	Renal cell carcinoma
Q56019530	Renal cell carcinoma
Q81628401	Renal cell carcinoma
Q82656838	Renal cell carcinoma
Q41235086	Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus
Q52584899	Renal cell carcinoma for the nephrologist.
Q42700879	Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients
Q77223839	Renal cell carcinoma in children with diffuse cystic hyperplasia of the kidneys
Q53352910	Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Q37998166	Renal cell carcinoma with clear cell and papillary features
Q82333868	Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study
Q72033651	Renal cell carcinoma. Cytogenetic analysis of tumors and cell lines
Q52724797	Renal cell carcinoma: a review of biology and pathophysiology.
Q42526854	Renal cell carcinoma: allelic loss at chromosome 9 using the fluorescent multiplex-polymerase chain reaction technique
Q34003335	Renal cell carcinoma: where will the state-of-the-art lead us?
Q36446896	Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor
Q71974434	Renal cysts, renal cancer and von Hippel-Lindau disease
Q33942236	Renal toxicity and carcinogenicity of trichloroethylene: key results, mechanisms, and controversies
Q34394356	Renal-cell carcinoma
Q35214956	Repeat partial nephrectomy: surgical, functional and oncological outcomes
Q36898383	Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
Q38274934	Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives
Q53211749	Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Q34387488	Review: cellular substrates of the eukaryotic chaperonin TRiC/CCT.
Q35990141	Role of VHL gene mutation in human cancer
Q33918504	Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis
Q45230739	Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein
Q37164607	Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor
Q33307879	Role of the ubiquitin proteasome system in renal cell carcinoma
Q28348758	Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
Q28208943	Roles of SCF and VHL ubiquitin ligases in regulation of cell growth
Q39544675	SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells
Q92977938	SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12
Q36694377	SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma
Q31030157	SU11248 and AG013736: current data and future trials in renal cell carcinoma
Q28272429	Safety and tolerability of pazopanib in the treatment of renal cell carcinoma
Q35705266	Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies
Q73130567	Screening for renal carcinoma associated mutations in the von Hippel-Lindau tumor suppressor gene by temperature gradient gel electrophoresis
Q34318015	Searching for the hereditary causes of renal-cell carcinoma
Q40019147	Segmental duplications and evolutionary plasticity at tumor chromosome break-prone regions
Q74509439	Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor
Q39697199	Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells.
Q38971171	Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism
Q47862165	Sequencing of the von Hippel-Lindau gene in canine renal carcinoma
Q46008845	Sequential sorafenib and sunitinib for renal cell carcinoma.
Q40038925	Signaling inhibitors in metastatic renal cell carcinoma
Q95935869	Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status
Q95807715	Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer
Q47101376	Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.
Q34618828	Single nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinoma
Q36895413	Small molecule signal transduction inhibitors for the treatment of solid tumors
Q39722266	Software and database for the analysis of mutations in the VHL gene
Q34286240	Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location.
Q27634727	Solution structure and dynamics of yeast elongin C in complex with a von Hippel-Lindau peptide
Q35238725	Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
Q73422570	Somatic mutation of the tuberous sclerosis (Tsc2) tumor suppressor gene in chemically induced rat renal carcinoma cell
Q71820124	Somatic mutations of von Hippel‐Lindau (VHL) tumor‐suppressor gene in european kidney cancers
Q77649713	Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion
Q44178387	Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney
Q34731411	Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis
Q36407379	Sorafenib
Q39431060	Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy
Q39637482	Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Q38431094	Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
Q36817095	Sorafenib: delivering a targeted drug to the right targets
Q53607782	Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: a retrospective analysis on computed tomography and magnetic resonance imaging studies.
Q71545608	Spontaneous renal tubular carcinoma in Fischer-344 rat littermates
Q33940347	Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes
Q79387201	Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene
Q24630685	State of the science: an update on renal cell carcinoma
Q39975802	State-of-the-art treatment of metastatic renal cell carcinoma.
Q38760019	Stem cells, biomarkers and genetic profiling: approaching future challenges in Urology
Q36367103	Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis
Q36945200	Structural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro
Q31085777	Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines
Q22009393	Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function
Q41194143	Studies of oncogene activation and tumor suppressor gene inactivation in normal and neoplastic rodent tissue
Q35044182	Studying cancer families to identify kidney cancer genes
Q37401350	Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation
Q41011329	Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
Q34969974	Subclassification of renal cell neoplasms: an update for the practising pathologist
Q46516706	Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
Q43194981	Sunitinib
Q37797460	Sunitinib for Metastatic Renal Cell Carcinoma
Q38206453	Sunitinib in the treatment of advanced solid tumors
Q28282757	Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Q35899174	Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma
Q37829355	Suppression of T-cell responses by tumor metabolites
Q54605056	Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element.
Q90558473	Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation
Q57545397	Surgical and Medical Options in the Management of Renal Cell Carcinoma
Q46358494	Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors
Q36395004	Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy
Q37341139	Surgical management of von Hippel-Lindau disease: urologic considerations
Q33848569	Surgical pathology of renal epithelial neoplasms: recent advances and current status
Q90092590	Surgical treatment for Xp11.2 translocation renal cell carcinoma with venous thrombus: A STROBE-compliant study
Q51625377	Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Q38709495	Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
Q24563543	Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
Q38216599	Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis
Q37575635	Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?
Q47591804	TCF21 hypermethylation regulates renal tumor cell clonogenic proliferation and migration
Q35293660	TFE3 Translocation-Associated Renal Cell Carcinoma Presenting as Avascular Necrosis of the Femur in a 19-Year-Old Patient: Case Report and Review of the Literature
Q47904057	THSD7A expression in human cancer
Q57291492	TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe
Q26995391	Targeted therapies and the treatment of non-clear cell renal cell carcinoma
Q39425380	Targeted therapies for renal cell carcinoma
Q37796392	Targeted therapies of cancer: Angiogenesis inhibition seems not enough
Q39914671	Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions
Q36597063	Targeted therapy for renal cell carcinoma: a new therapeutic paradigm
Q39943677	Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death
Q38750776	Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy
Q64253749	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys"
Q36380193	Targeting VEGF in cancer therapy
Q41930187	Targeting ion transport in cancer
Q33607412	Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
Q37684974	Targeting renal cell carcinoma with a HIF-2 antagonist.
Q37575541	Targeting the IGF1 axis in cancer proliferation
Q38668940	Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers.
Q90003131	Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression
Q38122564	Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma
Q40118469	Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.
Q28209316	Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein
Q51794179	Ternary complex formation of pVHL, elongin B and elongin C visualized in living cells by a fluorescence resonance energy transfer-fluorescence lifetime imaging microscopy technique.
Q91666595	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Q62606055	The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma
Q88633619	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma
Q51229854	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Q48027284	The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein
Q41509834	The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B.
Q24321912	The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers
Q40318935	The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma
Q37762200	The HIF-2α-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization
Q55067278	The Heidelberg classification of renal cell tumours.
Q92020314	The Metabolic Basis of Kidney Cancer
Q30277177	The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma
Q54299389	The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer.
Q88733594	The Role of DNA Methylation in Renal Cell Carcinoma
Q35971082	The Role of Elongin BC-Containing Ubiquitin Ligases
Q58199668	The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma
Q58199693	The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma
Q33683959	The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma
Q24676311	The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity
Q53088574	The VHL short variant involves in protein quality control.
Q37064867	The VHL tumor suppressor and HIF: insights from genetic studies in mice
Q36134573	The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.
Q80282025	The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma
Q24634592	The VHL tumor suppressor: master regulator of HIF
Q77572384	The VHL tumour-suppressor gene paradigm
Q92637492	The adjuvant treatment of kidney cancer: a multidisciplinary outlook
Q51002180	The allele frequency of two single nucleotide polymorphisms in the von Hippel-Lindau (VHL) tumor suppressor gene in the Taiwanese population.
Q73267658	The allelic loss of chromosome 3p25 with c‐myc gain is related to the development of clear‐cell renal cell carcinoma
Q43026364	The application of cytogenetics and fluorescence in situ hybridization to fine-needle aspiration in the diagnosis and subclassification of renal neoplasms
Q41899102	The bevacizumab experience in advanced renal cell carcinoma
Q36313089	The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis
Q37201797	The clinical implications of the genetics of renal cell carcinoma
Q55067670	The concise handbook of family cancer syndromes. Mayo Familial Cancer Program.
Q44043146	The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma
Q79240962	The correlation between the tumor necrosis and renal artery changes in renal cell carcinoma
Q39257795	The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney.
Q39021700	The epigenetic landscape of renal cancer
Q37770362	The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.
Q36825195	The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy
Q39257401	The experimental renal cell carcinoma model in the chick embryo
Q33536033	The genetic basis of breast cancer and its clinical implications
Q36048466	The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management
Q35591611	The genetic basis of cancer of the kidney
Q34087148	The genetic basis of kidney cancer: a metabolic disease
Q36067684	The genetic basis of pheochromocytoma and paraganglioma: implications for management
Q35210970	The genetic basis of renal cell carcinoma
Q34330265	The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy
Q80890715	The genetic make-up of renal cell tumors
Q35928846	The growing family of hereditary renal cell carcinoma
Q35454776	The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system
Q28582367	The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex
Q39404028	The interactome of CCT complex - A computational analysis
Q88937572	The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis
Q52094824	The management of familial breast cancer.
Q36437759	The molecular basis of von Hippel-Lindau disease
Q38131130	The molecular biology of renal cell carcinoma
Q96767193	The oncogenic role of MUC12 in RCC progression depends on c-Jun/TGF-β signalling
Q96828838	The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer
Q48345594	The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma
Q43244499	The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13.
Q40278749	The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy
Q36409967	The place of VEGF inhibition in the current management of renal cell carcinoma.
Q101154906	The prefoldin complex stabilizes the von Hippel-Lindau protein against aggregation and degradation
Q28296790	The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor alpha
Q35808120	The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease
Q34235680	The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy
Q33955367	The role of angiogenesis in prostate and other urologic cancers: a review
Q36121341	The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review)
Q93191323	The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review
Q48378117	The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma
Q77936208	The role of the FHIT/FRA3B locus in cancer
Q35794374	The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma
Q38001221	The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors
Q73863787	The tcf17 gene at chromosome 5q is not involved in the development of conventional renal cell carcinoma
Q39165782	The tumor-suppressive function of UNC5D and its repressed expression in renal cell carcinoma
Q22009936	The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Q90573376	The von Hippel Lindau tumour suppressor gene is a novel target of E2F4-mediated transcriptional repression in preeclampsia
Q43838634	The von Hippel-Lindau (VHL) disease tumor-suppressor gene is not mutated in nasopharyngeal carcinomas
Q35564185	The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing
Q99569784	The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities
Q37272653	The von Hippel-Lindau gene: turning discovery into therapy
Q34087732	The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression
Q37240022	The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL).
Q28206541	The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription
Q28203455	The von Hippel-Lindau tumor suppressor gene
Q33959078	The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells
Q34744818	The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
Q40023447	The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
Q40914048	The von Hippel-Lindau tumor suppressor gene product promotes, but is not essential for, NEDD8 conjugation to cullin-2.
Q35080738	The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells
Q41376765	The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis
Q30480543	The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth
Q28292043	The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery
Q35201819	The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
Q34748818	The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix
Q24304165	The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1
Q35863138	The von Hippel-Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform
Q33656394	The von Hippel-Lindau tumour suppressor protein: new perspectives
Q58068759	TheVon Hippel-Lindau (VHL) tumor-suppressor gene is not mutated in sporadic human colon adenocarcinomas
Q26747806	Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Q46863834	Therapy strategies for advanced renal cell carcinoma
Q96582600	Third-line sunitinib treatment in a VHL-mutated metastatic intrahepatic cholangiocarcinoma: a case report and literature review
Q78014839	This month in investigative urology. Kidney cancer: novel model for cancer genetics and therapy
Q44955205	Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma
Q53313789	Timeline: Chemotherapy and the war on cancer.
Q38114944	Tivozanib for the treatment of metastatic renal cancer
Q22254253	Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila
Q37353465	Transcription syndromes and the role of RNA polymerase II general transcription factors in human disease
Q24530637	Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein
Q47109274	Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients
Q46735182	Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
Q64981713	Treatment of renal-cell cancer by transplantation of allogeneic stem cells.
Q33385981	Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea
Q36398114	Trichloroethylene exposure and somatic mutations of the VHL gene in patients with Renal Cell Carcinoma
Q85849574	Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases
Q43739592	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma
Q37846387	Tumor biology and prognostic factors in renal cell carcinoma
Q35574224	Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase
Q91967463	Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families
Q28254125	Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma
Q33788736	Tumor suppressor genes in ophthalmology
Q58323648	Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth
Q34299645	Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent.
Q28206723	Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers
Q41320477	Tumour suppression by the human von Hippel-Lindau gene product
Q37610081	Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib
Q73111250	Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene
Q71747291	Two regions of homozygosity on chromosome 3p in squamous cell carcinoma of the head and neck: comparison with cytogenetic analysis
Q34208511	Two single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinoma
Q24321830	UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor gene
Q35082720	Ubiquitin pathway in VHL cancer syndrome
Q34152646	Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies
Q34115236	Ubiquitin/SUMO Modification Regulates VHL Protein Stability and Nucleocytoplasmic Localization
Q38265657	Ubiquitination in disease pathogenesis and treatment
Q64060129	Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma
Q24291981	Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein
Q88976865	Ubiquitination: Friend and foe in cancer
Q41765603	Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death.
Q38214357	Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity
Q26852398	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment
Q36397654	Understanding the importance of smart drugs in renal cell carcinoma
Q37765586	Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy
Q35789042	Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma
Q34456711	Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function
Q28140184	Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function
Q37642798	Update on novel agents in renal cell carcinoma
Q37165968	Update on the medical treatment of metastatic renal cell carcinoma
Q73461795	Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms
Q35038994	Use of the spontaneous Tsc2 knockout (Eker) rat model of hereditary renal cell carcinoma for the study of renal carcinogens
Q37774569	Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma
Q44011303	VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials
Q34406737	VEGF-targeted therapy in metastatic renal cell carcinoma
Q36409204	VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices
Q35332976	VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma
Q45770745	VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma
Q33862155	VHL and PTEN loss coordinate to promote mouse liver vascular lesions
Q33816341	VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis
Q53375202	VHL down-regulation and differential localization as mechanisms in tumorigenesis.
Q46268484	VHL gene alterations in Italian patients with isolated renal cell carcinomas
Q43728214	VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium
Q37393004	VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy
Q54627123	VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma.
Q27824781	VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma
Q44921292	VHL mutations in renal cell cancer: does occupational exposure to trichloroethylene make a difference?
Q81404373	VHL protein alterations in sporadic renal cell carcinoma
Q73707868	VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells
Q34455226	VHL, the story of a tumour suppressor gene
Q58584059	VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function
Q33568494	VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease
Q37166626	VHLdb: A database of von Hippel-Lindau protein interactors and mutations
Q92070638	VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects
Q37327806	Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma
Q33712289	Validation of housekeeping gene and impact on normalized gene expression in clear cell renal cell carcinoma: critical reassessment of YBX3/ZONAB/CSDA expression
Q39840596	Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer
Q55071101	Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma.
Q74455542	Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma
Q40106684	Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model
Q37463922	Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma
Q34091273	Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.
Q35584310	Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents
Q56068021	Von Hippel Lindau Syndrome
Q90184377	Von Hippel-Lindau "Black Forest" mutation inherited in a large Chinese family
Q55110633	Von Hippel-Lindau Disease.
Q56874444	Von Hippel-Lindau Syndrome
Q72201412	Von Hippel-Lindau disease
Q83009175	Von Hippel-Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastoma
Q51971299	Von Hippel-Lindau disease.
Q52372308	Von Hippel-Lindau disease.
Q54863226	Von Hippel-Lindau disease.
Q34305239	Von Hippel-Lindau disease: clinical and molecular perspectives
Q34448830	Von Hippel-Lindau disease: gene to bedside
Q35041278	Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function
Q41547229	Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene
Q34278652	Von Hippel-Lindau: how a rare disease illuminates cancer biology
Q44320068	Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor
Q36842042	What is standard initial systemic therapy in metastatic renal cell carcinoma?
Q26827754	When ubiquitin meets NF-κB: a trove for anti-cancer drug development
Q88555345	Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up
Q21245761	Wnt signaling pathways in urological cancers: past decades and still growing
Q35740118	ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer
Q82908362	[Angiogenesis: the renal cancer model]
Q54496744	[Genetics of paragangliomas and pheochromocytomas].
Q80687806	[Molecular biology of the clear cell renal cell carcinoma: principles for a selective treatment]
Q81886345	[Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer]
Q38328912	aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia
Q26775483	c-Met as a Target for Personalized Therapy
Q35161430	cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma
Q61813696	loss sensitizes cells to PI3Kβ and AKT inhibition
Q52922662	mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype.
Q35551941	miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma
Q35891149	miR-210: fine-tuning the hypoxic response
Q41353753	p53 status in spontaneous and dimethylnitrosamine-induced renal cell tumors from rats
Q54551413	pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma.
Q50913975	pVHL suppresses Akt/β-catenin-mediated cell proliferation by inhibiting 14-3-3ζ expression.
Q44480238	pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion.
Q34753344	pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation
Q28180159	von Hippel-Lindau disease
Q73567751	von Hippel-Lindau disease
Q73979850	von Hippel-Lindau disease
Q73492405	von Hippel-Lindau disease gene alterations associated with endolymphatic sac tumor
Q53456957	von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens.
Q24622030	von Hippel-Lindau disease: a clinical and scientific review
Q35117749	von Hippel-Lindau disease: recent advances and therapeutic perspectives.
Q35139869	von Hippel-Lindau exonic methylation analysis using MALDI-TOF mass spectrometry.
Q53428747	von Hippel-Lindau gene mutations in N-nitrosodimethylamine-induced rat renal epithelial tumors.
Q46478024	von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
Q44548991	von Hippel-Lindau protein complex is regulated by cell density

P6179	Dimensions Publication ID	1020232019
P356	DOI	10.1038/NG0594-85
P698	PubMed publication ID	7915601
P5875	ResearchGate publication ID	31934300

P2093	author name string	Li H
		Chen F
		Duh FM
		Latif F
		Tory K
		Liu S
		Schmidt L
		Gnarra JR
		Weng Y
		Wei MH
P2860	cites work	Mutations of the RET proto-oncogene in Hirschsprung's disease	Q24324643
		A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma	Q55670928
		Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC	Q57591365
		Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3;8 translocation. Genetics of familial renal carcinoma	Q70520141
		Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors	Q71666500
		The results of radical nephrectomy for renal cell carcinoma	Q72340879
		Identification of the von Hippel-Lindau disease tumor suppressor gene	Q29618644
		Von Hippel-Lindau disease: a genetic study	Q33597245
		Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers	Q34209006
		Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease	Q34336251
		von Hippel-Lindau disease affecting 43 members of a single kindred	Q38596547
		Hereditary papillary renal cell carcinoma	Q40814773
		Cytogenetics of papillary renal cell tumors	Q41676155
		Hereditary Renal-Cell Carcinoma Associated with a Chromosomal Translocation	Q41751694
		Establishment and characterization of a cell line (SS78) from a human renal cell carcinoma	Q42801958
		Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.	Q48114164
		Human renal carcinoma: characterization of five new cell lines.	Q53437651
		Tumor suppressor gene allelic loss in human renal cancers.	Q53477783
P4510	describes a project that uses	SK-RC-62	Q54954637
		SK-RC-8	Q54954641
		SK-RC-9	Q54954642
		SS78	Q54955686
		UM-RC-11	Q54990782
		UM-RC-2	Q54990783
		UM-RC-3	Q54990784
		UM-RC-5	Q54990785
		UM-RC-6	Q54990787
		UM-RC-7	Q54990788
		UOK101	Q54991268
		UOK102	Q54991269
		UOK110	Q54991282
		UOK111	Q54991285
		UOK115	Q54991318
		UOK117	Q54991322
		UOK118	Q54991328
		UOK123	Q54991342
		UOK130	Q54991357
		UOK135	Q54991365
		UOK139	Q54991370
		UOK140	Q54991371
		UOK141	Q54991373
		UOK142	Q54991375
		UOK150	Q54991380
		UOK151	Q54991381
		UOK154	Q54991384
		UOK161	Q54991407
		UOK162	Q54991408
		UOK163	Q54991409
		UOK164	Q54991410
		786-O	Q54604950
		A-498	Q54606041
		KTCTL-13	Q54900630
		KTCTL-140	Q54900633
		KTCTL-2	Q54900639
		KTCTL-26A	Q54900643
		KTCTL-53	Q54900650
		SK-RC-28	Q54954564
		SK-RC-48	Q54954595
		SK-RC-61	Q54954614
P433	issue	1
P407	language of work or name	English	Q1860
P921	main subject	cell line	Q21014462
P304	page(s)	85-90
P577	publication date	1994-05-01
P1433	published in	Nature Genetics	Q976454
P1476	title	Mutations of the VHL tumour suppressor gene in renal carcinoma
P478	volume	7

Q54604950	786-O
Q54606041	A-498
Q54900630	KTCTL-13
Q54900633	KTCTL-140
Q54900639	KTCTL-2
Q54900643	KTCTL-26A
Q54900650	KTCTL-53
Q54954564	SK-RC-28
Q54954595	SK-RC-48
Q54954614	SK-RC-61
Q54954637	SK-RC-62
Q54954641	SK-RC-8
Q54954642	SK-RC-9
Q54955686	SS78
Q54990782	UM-RC-11
Q54990783	UM-RC-2
Q54990784	UM-RC-3
Q54990785	UM-RC-5
Q54990787	UM-RC-6
Q54990788	UM-RC-7
Q54991268	UOK101
Q54991269	UOK102
Q54991282	UOK110
Q54991285	UOK111
Q54991318	UOK115
Q54991322	UOK117
Q54991328	UOK118
Q54991342	UOK123
Q54991357	UOK130
Q54991365	UOK135
Q54991370	UOK139
Q54991371	UOK140
Q54991373	UOK141
Q54991375	UOK142
Q54991380	UOK150
Q54991381	UOK151
Q54991384	UOK154
Q54991407	UOK161
Q54991408	UOK162
Q54991409	UOK163
Q54991410	UOK164

Mutations of the VHL tumour suppressor gene in renal carcinoma

scientific article published on May 1994

Reverse relations